Big Picture Bio
London company founded in January 2026 and built at Deep Science Ventures, using a generative world model of tumour, immune and tissue interactions to design cancer combination therapies; it is moving its first AI-designed combinations out of in-silico work into wet-lab validation.
Headquarters
London, United Kingdom
Year Founded
2026
Founders
Kerstin Papenfuss (CEO), Mark Hammond (CTO)
Country
United Kingdom
Financial Information
Funding Stage
Pre-Seed
Recent Funding
GBP 2.2M
Funding By
Kadmos Capital, Exceptional Ventures, Gloucester Ventures, Innovate UK (grant)
Core Technology
Generative world model of tumour-immune-tissue interactions
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Not disclosed
Academic / Hospital Tie-ups
Deep Science Ventures (venture creation)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Designs combination regimens rather than single agents, testing resistance hypotheses in silico first